NANOBIOTIX to Enter CAC Mid 60 and SBF 120 Indices

NANOBIOTIX, a biotechnology company known for pioneering physics-based approaches in cancer treatment, announced its inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after market close on December 19, 2025. These indices are leading benchmarks for mid-sized and prominent companies in France.

Inclusion in these indices is anticipated to enhance Nanobiotix's visibility among institutional investors and strengthen its presence in European equity markets. CEO Laurent Levy expressed that this inclusion reflects positive market confidence in the company's long-term strategy and disruptive potential.

Nanobiotix is committed to advancing its nanotherapeutic solutions and creating sustainable value. The company's focus remains on disciplined execution as it progresses toward key milestones in expanding physics-based medicine frontiers.